SOTIO is a clinical stage biotechnology company developing a new Active Cellular Immunotherapy (_ACIÓ) based on activated dendritic cells for the treatment of cancer and autoimmune diseases.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/sotio-a.s.” connections=”true” suffix=””]
SOTIOs proprietary ACI-MAP (Active Cellular Immunotherapy Multiple Antigen Presentation) technology, the patients own dendritic cells, are activated by a broad range of tumor antigens, to induce a complex immune response.
In Aug 2018, SOTIO, acquired Cytune Pharma developing IL-15 based therapies for the treatment of cancer. Cytunes lead molecule, SO-C101 (RLI-15), is a human fusion protein of IL-15 and the high-affinity binding domain of IL-15R? and acts as a specific IL-2/IL-15R?? agonist. The financial terms of the transaction are not disclosed.